Axitinib

Red

Brand Name(s):Inlyta

Indication:Renal cell carcionoma (advanced)

Rationale:1,2

Considered:Jul-12

Review Date:Mar-20

Comments:
NICE TA 333
NICE recommends axitinib as a possible treatment for adults with advanced renal cell carcinoma when drugs called tyrosine kinase inhibitors or cytokines have not worked.

Document available at: https://www.nice.org.uk/guidance/ta333/resources/guidance-axitinib-for-treating-advanced-renal-cell-carcinoma-after-failure-of-prior-systemic-treatment-pdf
Feb 2015